The everolimus/exemestane combination was approved in more than 100 countries for patients with advanced hormone receptor-positive HER2-negative breast cancers, based on the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) phase III trial [34, 35]. This evidence concerns the gene NR4A1 and breast cancer.